Theravance has announced the appointment of Theodore J. Witek, Jr. as Senior VP Corporate Partnerships, Clinical and Medical Affairs. In that capacity, the company says Witek “will be focused on the further development of the respiratory programs partnered with Glaxo Group Limited (GSK),” including the Anoro and Breo/Ellipta DPIs. Witek was most recently President and CEO of Boehringer Ingelheim Canada.
Witek joined Boehringer Ingelheim in 1992 and had various roles in the development of respiratory products, including leading the Respiratory and Immunology clinical research groups in the US and leading clinical development for Spiriva. He was VP Respiratory Global Operations for BI from 2000-2004.
Theravance CEO Rick E. Winningham commented, “Ted’s robust clinical, regulatory and medical affairs experience in respiratory disease will be fundamental to achieving our corporate objective of maximizing the value of our partnership with GSK. Ted will join a growing senior leadership team at Theravance, a team dedicated to the creation of value for patients and stockholders.”
Reas the Theravance press release.
